Challenges in manufacturing and distributing products derived from biologics | Hedley Rees
6 September 2023 | The pharmaceutical industry was founded on small molecule products, where active ingredients were manufactured by fine chemical companies using long-established industrial processing. That meant the final dosage forms had excellent stability profiles with a typical shelf-life between two to five years. The simple chemical structures meant that different producers’ products could be tested against specifications and proven to be equivalent and therefore interchangeable. Storage conditions, in the main, were controlled room temperature (20°C), which was relatively easy to maintain within the required +/- 5°C in pharmaceutical warehouses of the day.
Fast forward to today’s industry and the emergence of biologics—products made from living things. With the success of biologics such as monoclonal antibodies in treating certain diseases, rapid growth in this new type of drug ensued. The latest development in biologics is advanced therapy medicinal products (ATMPs).
This presentation delves into the specific supply chain and regulatory compliance challenges, and risks to patient safety, associated with biologics and ATMPs.
Hedley Rees has been running the UK-based consultancy PharmaFlow since 2005, specialising in operations and supply chain management in the biopharmaceutical industry. Hedley’s expertise is in the three phases of clinical trials (and preclinical if required) and ongoing distribution of products that have gained regulatory authorisations to market. Prior to that, he spent 16 years in senior roles in Big Pharma (Bayer) and 10 years in biotech (British Biotech, Vernalis and OSI Pharmaceuticals, now Astellas). Hedley is also a long-term advocate of paradigm shifting modernization in the biopharmaceutical industry, authoring Supply Chain Management in the Drug Industry: Delivering Patient Value for Pharmaceuticals and Biologics, published by Wiley, NJ in 2011. His next book for Wiley has the provisional title A Systems-Based Approach to Transforming Pharmaceutical Supply Chains: Transitioning from Patents to Patients, to be published in response to the many questions that have arisen during the C19 enigma.
PANDA’s weekly Open Science Sessions provide an opportunity for science, research and policy to be presented by various leading international experts in a variety of diverse fields. These sessions aim to broaden understanding and inspire new insights.
Support our work: www.pandata.org/donate/
-
1:27:10
PANDA | Science. Sense. Society.
2 months agoThe UK Government’s use of behavioural science strategies in their Covid messaging | Dr Gary Sidley
6423 -
LIVE
Matt Kim
47 minutes agoDoes America Need God? w/ Pastor Doug Wilson | Matt Kim #098
463 watching -
1:25:11
Russell Brand
2 hours agoBREAKING: Russia Sends Hypersonic Missiles & Subs To CUBA! Biden Getting His WW3!
34.3K128 -
1:16:24
Dr. Drew
23 hours agoWinston Marshall: In Debate With Nancy Pelosi, Grammy Winner (Mumford & Sons) Tells Congresswoman She's A Bigger Threat To Democracy Than "Populism" – Ask Dr. Drew
28.3K13 -
DVR
Neil
1 hour agoA RETAIL APOCALYPSE IS UPON US!
2.52K -
LIVE
TheAlecLaceShow
3 hours agoNancy Pelosi Claims Responsibility For J6 | Hunter is Guilty | A Face of Evil | The Alec Lace Show
831 watching -
59:15
The Dan Bongino Show
3 hours agoThe REAL January 6th Story Is Starting To Come Out (Ep. 2268) - 06/11/2024
276K1.51K -
LIVE
Benny Johnson
2 hours agoBREAKING: Hunter Biden Found GUILTY on ALL COUNTS | Libs Have PANIC ATTACK at Court 🚨
14,171 watching -
1:33:13
vivafrei
3 hours agoJan. 6 LIHOP Confirmed! "Treason" in Canada? Fani Willis the "Ho"? Viva Frei LIVE!
28.9K36 -
1:57:21
Steven Crowder
4 hours agoNashville Manifesto Update: 80 NEW Pages of Shooter’s Writings | GUEST: Michael Patrick Leahy
220K254